Information Provided By:
Fly News Breaks for April 27, 2015
CLDN
Apr 27, 2015 | 06:32 EDT
Roth Capital downgraded Celladon to Neutral with a $2 price target following neagive results for CUPID2 Trial of MYDICAR in advanced heart failure.
News For CLDN From the Last 2 Days
There are no results for your query CLDN